INCEPT: The Intensive Care Platform Trial-Design and protocol.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Granholm Anders, Møller Morten Hylander, Kaas-Hansen Benjamin Skov, Jensen Aksel Karl Georg, Munch Marie Warrer, Kjær Maj-Brit Nørregaard, Andersen Lars Wiuff, Schjørring Olav Lilleholt, Rasmussen Bodil Steen, Meyhoff Tine Sylvest, Larsen Rikke Faebo, Thorsen-Meyer Hans-Christian, Collet Marie Oxenbøll, Meier Nick Frørup, Estrup Stine, Mathiesen Ole, Maagaard Mathias, Poulsen Lone Musaeus, Strøm Thomas, Christensen Steffen, Bruun Camilla Rahbek Lysholm, Keus Frederik, Rossing Peter, Granfeldt Asger, Brøchner Anne Craveiro, Itenov Theis Skovsgaard, Cronhjort Maria, Laake Jon Henrik, Hästbacka Johanna, Pfortmueller Carmen Andrea, Siegemund Martin, Sigurdsson Martin Ingi, Andersen Lars Peter Kloster, Placido Davide, Lange Theis, Perner Anders
Аннотация
METHODS: The Intensive Care Platform Trial (INCEPT) is an investigator-initiated, pragmatic, randomised, embedded, multifactorial, international, adaptive platform trial including adults acutely admitted to ICUs. INCEPT will assess comparable groups of interventions (primarily commonly used interventions with clinical uncertainty and practice variation) nested in domains. Interventions may be either open-label or masked. New domains will continuously be added to the platform. INCEPT assesses multiple core outcomes selected following substantial stakeholder involvement: mortality, days alive without life support/out of hospital/free of delirium, health-related quality of life, cognitive function, and safety outcomes. Each domain will use one of these core outcomes as the primary outcome. INCEPT primarily uses Bayesian statistical methods with neutral, minimally informative or sceptical priors, adjustment for important prognostic baseline variables, and calculation of absolute and relative differences in the intention-to-treat populations. Domains and intervention arms may be stopped for superiority/inferiority, practical equivalence, or futility according to pre-specified adaptation rules evaluated using statistical simulation or at pre-specified maximum sample sizes. Domains may use response-adaptive randomisation, meaning that more participants will be allocated to interventions with higher probabilities of being superior.
CONCLUSIONS: INCEPT provides an efficient, pragmatic, and flexible platform for comparing the effects of many interventions used in adult ICU patients. The adaptive design enables the trial to use accumulating data to improve the treatment of future participants. INCEPT will provide high-certainty, conclusive evidence for many interventions, directly inform clinical practice, and thus improve patient-important outcomes.